- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GEOPHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 28,870 | -0,03 % | Ionis Pharmaceuticals, Inc.: Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. | - Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world - - Ionis will continue to independently commercialize TRYNGOLZA (olezarsen)... ► Artikel lesen | |
| CSPC PHARMA | 0,639 | -3,50 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION | ||
| ACADIA PHARMACEUTICALS | 15,555 | -1,18 % | Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders | ||
| SELLAS LIFE SCIENCES | 1,436 | 0,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML | NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 253,40 | -2,80 % | Madrigal's liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis | ||
| CATALYST PHARMACEUTICALS | 21,280 | +0,05 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals | CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,071 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
| OPUS GENETICS | 0,866 | +2,36 % | Opus Genetics, Inc. - 10-Q, Quarterly Report | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets | Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,010 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
| SAVARA | 2,680 | -3,60 % | Savara GAAP EPS of -$0.12 beats by $0.01 | ||
| GALECTIN THERAPEUTICS | 1,170 | -0,85 % | Galectin Therapeutics GAAP EPS of -$0.15 | ||
| BIODEXA PHARMACEUTICALS | 1,290 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP | May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted... ► Artikel lesen | |
| SCICLONE PHARMACEUTICALS | - | - | Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone | TOKYO, Feb 28, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 0,080 | 0,00 % | NovaBay Pharmaceuticals, Inc. - 10-Q, Quarterly Report |
GEOPHARMA INC gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GEOPHARMA INC finden Sie auf Wallstreet Online.